Further, until now, all influenza vaccines have been produced in biologically living cells. Whether whole virus or recombinant virus sections are reproduced in eggs, kidney, hamster, E.coli, or other cells, these living cells provide the obligatory contamination in the vaccine of thousands of unwanted immunogenic proteins, the potential for other virus contamination (viruses only reproduce in living cells), and the need for potentially toxic preservatives.
Over the last decade, Drs. Samuel and Elenore Bogoch have been developing vaccine-manufacturing methods that are non-biological, based on software algorithms designed to study virus structure, and organic chemistry. The new, completely synthetic Replikins(TM) Vaccine Technology1-4 targets a group of genomic peptides that they discovered and named Replikins(TM). These genomic peptides were found to be conserved in viruses cross-strain over decades, and to be related to rapid replication and epidemic outbreaks.
The centrality of the Replikins(TM) to influenza has been confirmed recently by the data of two independent groups, Harvard-CDC and Scripps-Crucell. Their findings demonstrate that inhibitory antibody lands on and binds selectively to the very peptides that the Drs. Bogoch have previously identified as Replikins(TM).
Three months to one year in advance of an outbreak, the related Replikins(TM) FluForecast(R) software warns of the oncoming emergent disease. This technology was recently validated when it successfully identified, a year in advance, the current H1N1 outbreak. The technology also defines the Replikins(TM) that need to be synthesized in the vaccine. Thus the Replikins(TM) structures, which make up both the newly discovered infectivity and lethality genes within the virus genome, provide the keys to both advance warning and synthetic vaccine production.
|SOURCE Replikins Ltd.|
Copyright©2009 PR Newswire.
All rights reserved